Drug Approval | May 12, 2022
OvaCis rapid test to detect ovarian cancer gets CE mark
Revolutionary ovarian cancer rapid test available Q4 2022
Revolutionary ovarian cancer rapid test available Q4 2022
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
It affects up to 10 per cent of women of reproductive age around the world
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Vacuum-Assisted Breast Biopsy (VABB) is an innovative and more effective alternative to the traditional method where benign lumps are removed surgically, leaving scars and causing distress
The data driven fertility company helps increase the success rate of fertility treatments
These melas serve as platforms to attract thousands of people to avail quality healthcare services along with essential medicines and diagnostic services
The total investment is in the region of Rs 200 crore
Subscribe To Our Newsletter & Stay Updated
